Biophan CEO Michael Wiener to Present Latest R&D and Business Milestones at Financial Services Exchange Meeting; CEO to Discuss Growth of Company's Technology Portfolio and Product Development for Global Biomedical Markets
In a 30-minute presentation, Biophan CEO Michael Wiener will acquaint attending members of the financial and investment community with Biophan's technologies, including solutions that make implantable medical devices safe and image-compatible with Magnetic Resonance Imaging (MRI) systems. Mr. Weiner will describe how these technologies can be applied to a range of existing and emerging multi-billion-dollar markets in biosciences and healthcare.
“The last several months have been particularly productive for Biophan”
"The last several months have been particularly productive for Biophan," said Mr. Wiener. "I look forward to telling the investment professionals at the Financial Services Exchange conference about the Company's latest achievements--including our recently executed definitive agreements with Boston Scientific, one of the world's largest and most innovative manufacturers of medical devices--and steps we are taking to continue building shareholder value through the development of important biomedical technologies and solutions."
For more information about the Financial Services Exchange, please visit: http://fsxone.com.
About Financial Services Exchange
Financial Services Exchange (FSX Inc.) was founded in 1983. FSX is a national organization of Independent NASD Broker Dealer firms, whose purpose is to bring NASD member firms together to share information, provide education and showcase investment opportunities.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents. Biophan is developing other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 142 U.S. patents, licenses, or applications. This total includes 38 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 95 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE: BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.